Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:15:26.588Z.
Calculation as of: 2026-10-06T16:15:26.588Z.
Quote observation: 2026-10-06T16:15:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ecad0762b01eca72400a5d6f6e26675042e53628e137481382d213c8e973aca5
PEG RATIO
N/A
Acadia Pharmaceuticals Inc.
Market Cap
$3.42B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.42B | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.42B | N/A |
| CareDx, Inc (CDNA)vs › | $3.40B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A |
| Celcuity Inc. (CELC)vs › | $3.52B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.52B | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.60B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.13B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | N/A |
PEG Ratio
N/A
P/E Ratio
9.0
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
